Improving on the standard of care for diseases is predicated on better treatments, which in turn relies on finding and developing new drugs. However, drug discovery is a complex and costly process. Adoption of methods from machine learning has given rise to creation of drug discovery knowledge graphs which utilize the inherent interconnected nature of the domain. Graph-based data modelling, combined with knowledge graph embeddings provide a more intuitive representation of the domain and are suitable for inference tasks such as predicting missing links. One such example would be producing ranked lists of likely associated genes for a given disease, often referred to as target discovery. It is thus critical that these predictions are not only pertinent but also biologically meaningful. However, knowledge graphs can be biased either directly due to the underlying data sources that are integrated or due to modeling choices in the construction of the graph, one consequence of which is that certain entities can get topologically overrepresented. We show how knowledge graph embedding models can be affected by this structural imbalance, resulting in densely connected entities being highly ranked no matter the context. We provide support for this observation across different datasets, models and predictive tasks. Further, we show how the graph topology can be perturbed to artificially alter the rank of a gene via random, biologically meaningless information. This suggests that such models can be more influenced by the frequency of entities rather than biological information encoded in the relations, creating issues when entity frequency is not a true reflection of underlying data. Our results highlight the importance of data modeling choices and emphasizes the need for practitioners to be mindful of these issues when interpreting model outputs and during knowledge graph composition.
In recent years, numerous machine learning models which attempt to solve polypharmacy side effect identification, drug-drug interaction prediction and combination therapy design tasks have been proposed. Here, we present a unified theoretical view of relational machine learning models which can address these tasks. We provide fundamental definitions, compare existing model architectures and discuss performance metrics, datasets and evaluation protocols. In addition, we emphasize possible high impact applications and important future research directions in this domain.
In recent years, numerous machine learning models which attempt to solve polypharmacy side effect identification, drug-drug interaction prediction and combination therapy design tasks have been proposed. Here, we present a unified theoretical view of relational machine learning models which can address these tasks. We provide fundamental definitions, compare existing model architectures and discuss performance metrics, datasets and evaluation protocols. In addition, we emphasize possible high impact applications and important future research directions in this domain.
Knowledge Graphs (KG) and associated Knowledge Graph Embedding (KGE) models have recently begun to be explored in the context of drug discovery and have the potential to assist in key challenges such as target identification. In the drug discovery domain, KGs can be employed as part of a process which can result in lab-based experiments being performed, or impact on other decisions, incurring significant time and financial costs and most importantly, ultimately influencing patient healthcare. For KGE models to have impact in this domain, a better understanding of not only of performance, but also the various factors which determine it, is required. In this study we investigate, over the course of many thousands of experiments, the predictive performance of five KGE models on two public drug discovery-oriented KGs. Our goal is not to focus on the best overall model or configuration, instead we take a deeper look at how performance can be affected by changes in the training setup, choice of hyperparameters, model parameter initialisation seed and different splits of the datasets. Our results highlight that these factors have significant impact on performance and can even affect the ranking of models. Indeed these factors should be reported along with model architectures to ensure complete reproducibility and fair comparisons of future work, and we argue this is critical for the acceptance of use, and impact of KGEs in a biomedical setting. To aid reproducibility of our own work, we release all experimentation code.
The drug discovery and development process is a long and expensive one, costing over 1 billion USD on average per drug and taking 10-15 years. To reduce the high levels of attrition throughout the process, there has been a growing interest in applying machine learning methodologies to various stages of drug discovery process in the recent decade, including at the earliest stage - identification of druggable disease genes. In this paper, we have developed a new tensor factorisation model to predict potential drug targets (i.e.,genes or proteins) for diseases. We created a three dimensional tensor which consists of 1,048 targets, 860 diseases and 230,011 evidence attributes and clinical outcomes connecting them, using data extracted from the Open Targets and PharmaProjects databases. We enriched the data with gene representations learned from a drug discovery-oriented knowledge graph and applied our proposed method to predict the clinical outcomes for unseen target and dis-ease pairs. We designed three evaluation strategies to measure the prediction performance and benchmarked several commonly used machine learning classifiers together with matrix and tensor factorisation methods. The result shows that incorporating knowledge graph embeddings significantly improves the prediction accuracy and that training tensor factorisation alongside a dense neural network outperforms other methods. In summary, our framework combines two actively studied machine learning approaches to disease target identification, tensor factorisation and knowledge graph representation learning, which could be a promising avenue for further exploration in data-driven drug discovery.
Drug discovery and development is an extremely complex process, with high attrition contributing to the costs of delivering new medicines to patients. Recently, various machine learning approaches have been proposed and investigated to help improve the effectiveness and speed of multiple stages of the drug discovery pipeline. Among these techniques, it is especially those using Knowledge Graphs that are proving to have considerable promise across a range of tasks, including drug repurposing, drug toxicity prediction and target gene-disease prioritisation. In such a knowledge graph-based representation of drug discovery domains, crucial elements including genes, diseases and drugs are represented as entities or vertices, whilst relationships or edges between them indicate some level of interaction. For example, an edge between a disease and drug entity might represent a successful clinical trial, or an edge between two drug entities could indicate a potentially harmful interaction. In order to construct high-quality and ultimately informative knowledge graphs however, suitable data and information is of course required. In this review, we detail publicly available primary data sources containing information suitable for use in constructing various drug discovery focused knowledge graphs. We aim to help guide machine learning and knowledge graph practitioners who are interested in applying new techniques to the drug discovery field, but who may be unfamiliar with the relevant data sources. Overall we hope this review will help motivate more machine learning researchers to explore combining knowledge graphs and machine learning to help solve key and emerging questions in the drug discovery domain.
With the growing significance of graphs as an effective representation of data in numerous applications, efficient graph analysis using modern machine learning is receiving a growing level of attention. Deep learning approaches often operate over the entire adjacency matrix -- as the input and intermediate network layers are all designed in proportion to the size of the adjacency matrix -- leading to intensive computation and large memory requirements as the graph size increases. It is therefore desirable to identify efficient measures to reduce both run-time and memory requirements allowing for the analysis of the largest graphs possible. The use of reduced precision operations within the forward and backward passes of a deep neural network along with novel specialised hardware in modern GPUs can offer promising avenues towards efficiency. In this paper, we provide an in-depth exploration of the use of reduced-precision operations, easily integrable into the highly popular PyTorch framework, and an analysis of the effects of Tensor Cores on graph convolutional neural networks. We perform an extensive experimental evaluation of three GPU architectures and two widely-used graph analysis tasks (vertex classification and link prediction) using well-known benchmark and synthetically generated datasets. Thus allowing us to make important observations on the effects of reduced-precision operations and Tensor Cores on computational and memory usage of graph convolutional neural networks -- often neglected in the literature.